NEW YORK (GenomeWeb) – Quest Diagnostics has signed a reference agreement to offer Biocept's Target Selector mutation detection test for lung cancer in Mexico.
Under the terms of the agreement, Quest will perform the blood test for EGFR mutations in that country. Financial and other terms of the agreement were not disclosed.
"Our ability to expand internationally is a testament to the scalability of our platform as we deliver liquid biopsy testing to the medical community worldwide," Biocept President and CEO Michael Nall said in a statement.
Biocept offers liquid biopsies for lung, breast, gastric, colorectal, prostate, and skin cancers. Its Target Selector platform captures and analyzes both cellular and cell-free circulating tumor DNA, to find mutations associated with those cancers.
"Detecting the EGFR mutation can qualify patients for targeted therapy treatments that could lead to better outcomes," Biocept VP of Commercial Operations Raaj Trivedi added.
The deal is the latest international agreement for San Diego-based Biocept. Las month, the firm signed a marketing and distribution agreement for Israel with Tel Aviv-based Progenetics.